Actithera Expands Horizons with Revolutionary Chemistry Technologies
Actithera, a forward-thinking biotechnology firm, has announced an exclusive license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, granting access to innovative patent families that focus on advanced covalent chemistry technologies. This groundbreaking development allows Actithera to enhance its drug discovery and development capabilities in the radiopharmaceutical sector.
Innovative Approaches to Radiopharmaceuticals
These patented technologies, refined in the lab of renowned Professor Nir London, are set to transform the landscape of radiopharmaceuticals. By employing site-specific, durable, and traceless protein radiolabeling methods, Actithera aims to significantly increase tumor selectivity and retention, which is critical for effective cancer therapies.
Leveraging Academic Innovation for Cancer Therapy
With these new methodologies, Actithera is positioning itself at the forefront of oncological advancements. By integrating these distinctive covalent chemistry techniques into its existing platforms, the company intends to develop next-generation radioligand therapies targeting various oncology indications. This strategic integration is crucial for improving treatment outcomes for patients suffering from cancer.
Leadership Insight on the Agreement
Andreas Goutopoulos, PhD, the Founder and CEO of Actithera, expressed enthusiasm for this partnership, emphasizing its potential to revolutionize cancer treatment. He stated, "This agreement represents a significant advancement for Actithera. By incorporating Professor London's pioneering chemistry into our proprietary toolkit, we uniquely position ourselves to unlock new avenues in cancer therapy. This innovation enables us to deliver radioactivity directly into tumor cells by irreversibly and tracelessly tagging tumor-specific proteins, preserving their natural structure while aiming for better therapeutic results."
Collaboration with Yeda
Elik Chapnik, PhD, CEO of Yeda, commented on the collaboration, highlighting Actithera's vision as a perfect fit for translating scientific breakthroughs into impactful cancer treatments. "We are excited to collaborate with Actithera in bridging these groundbreaking discoveries to benefit patients worldwide," he noted.
Advancing Clinical Development
The introduction of these technologies comes at a pivotal time for Actithera as it advances its lead FAP-targeting radioligand candidate into clinical development for multiple indications. This growth is bolstered by a recent oversubscribed financing of $75.5 million in a Series A funding round, completed in July 2025.
Professor London’s Perspective
Professor Nir London shared his excitement regarding the partnership with Actithera. He stated that his lab's commitment to enhancing covalent drug design is manifesting strongly in the form of these technological advancements that may deliver targeted radiation directly to tumors while minimizing damage to healthy tissue. He looks forward to assisting Actithera in advancing these technologies through the clinical validation process.
Building a Pipeline of Precision Therapies
The licensing agreement marks just one of several transformative approaches being adopted by Actithera as they enhance their discovery engine. This expansion of capabilities aims to tackle significant unmet needs in oncology, ensuring that Actithera continues to pioneer new solutions in cancer treatment.
About Actithera
Actithera is a cutting-edge biotechnology company based in Cambridge and Oslo, specializing in the development of next-generation radiopharmaceutical therapies. Combining expertise in medicinal chemistry, radiochemistry, and drug design, Actithera is dedicated to creating novel targeted therapies for cancer treatment.
About Yeda
Yeda, associated with the Weizmann Institute of Science, plays a crucial role in translating groundbreaking scientific discoveries into life-changing therapeutic products. The organization prides itself on forged partnerships that pave the way for the commercialization of innovative drugs worldwide.
About the Weizmann Institute of Science
As one of the world's premier research institutions, the Weizmann Institute of Science engages in multidisciplinary studies across various scientific fields. Their work spans crucial research on cancer, AI technology, environmental issues, and more, striving to generate impactful solutions for global challenges.
Frequently Asked Questions
What is Actithera’s recent achievement?
Actithera secured an exclusive license for innovative covalent chemistry technologies from Yeda, associated with the Weizmann Institute.
What are the benefits of the licensed technologies?
The technologies are designed for enhancing targeting and retention of radiopharmaceuticals in tumor cells, improving cancer treatment outcomes.
Who is Professor Nir London?
Professor Nir London is an esteemed leader in covalent drug design, whose lab developed the technologies licensed to Actithera.
What will Actithera do with the new technologies?
Actithera will integrate these technologies into its existing radiopharmaceutical discovery platform to advance clinical development of its therapies.
How does this partnership impact cancer treatment?
This collaboration aims to bring innovative targeted therapies to market, significantly benefiting cancer patients by improving treatment efficacy.
